Cipla gains 1% on partnership with Roche Pharma

The company entered into an agreement with Roche Pharma under which Cipla will promote and distribute tocilizumab (Actemra) and Syndyma, the 2nd brand of Roche’s cancer therapy, bevacizumab (Avastin) in India.

Shares of Cipla rose 1 percent in the early trade Wednesday on a partnership with Roche Pharma.


Equity Service


The company entered into an agreement with Roche Pharma under which Cipla will promote and distribute Tocilizumab (Actemra) and Syndyma, the 2nd brand of Roche’s cancer therapy, bevacizumab (Avastin) in India.
This partnership is in line with Cipla and Roche’s efforts to improve healthcare and increase access to innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.

Umang Vohra, MD & Global CEO of Cipla said, “The prevalence of cancer and rheumatoid arthritis is widely spread across India, and Cipla can contribute to providing broader access to innovative medicines like tocilizumab and bevacizumab. We look forward to promoting and distributing the drugs in India in furtherance of our philosophy of Caring for Life.”


At 09:20 hrs Cipla was quoting at Rs 593, up Rs 6.85, or 1.17 percent on the BSE.

Two days Free Trials and best services packages for dealing in Stock market click here to get >> Equity Service One Missed call on @9644405056

Comments

Popular posts from this blog

Daily equity Market By Ripplesadvisory Report 16-Aug-2016

सकारात्मक वैश्विक रुझानों के सहारे बाजार में मजबूती, निफ्टी 10,900 के ऊपर

11-year data suggests bears control D-Street in September; can bulls defy odds?